Real-world data and upcoming research highlight the effectiveness of BIC/FTC/TAF switching and long-acting ART for HIV patients, with ViiV Healthcare set to present phase IIIb trial results at AIDS 2026.
Real-world evidence published in health.nsw.gov.au and Therapy and Clinical Infectious Diseases underscores the safety and efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for virologically suppressed HIV patients, while long-acting antiretroviral therapy (ART) shows promise for those with viremia. These findings align with ViiV Healthcare’s upcoming presentations at the 26 th International AIDS Conference, where phase IIIb trial data and real-world outcomes for long-acting injectables will be shared.
Real-World Data on BIC/FTC/TAF Switch
A study published in Infectious Diseases and Therapy found that switching to BIC/FTC/TAF is a safe and effective regimen-optimization strategy for adults with HIV who are virologically suppressed on antiretroviral therapy. The research, based on real-world data, supports the use of this combination in clinical practice, particularly for patients seeking simplified treatment regimens. This aligns with broader efforts to improve adherence and reduce the pill burden for long-term HIV management.
The data also highlight the importance of monitoring viral load and resistance patterns during regimen changes. While BIC/FTC/TAF is generally well-tolerated, clinicians are advised to assess individual patient profiles before initiating the switch. The findings reinforce the role of BIC/FTC/TAF as a cornerstone of modern HIV treatment, particularly in resource-limited settings where adherence to daily oral medications can be challenging.
Long-Acting ART Achieves Virologic Suppression in Viremic Patients
Research presented in Clinical Infectious Diseases demonstrates that long-acting ART, including injectable formulations, can achieve virologic suppression in patients with HIV who are viremic at initiation. This is a critical development, as it expands treatment options for individuals who may struggle with daily medication adherence. The study emphasizes the potential of long-acting therapies to improve outcomes in diverse patient populations, including those with high viral loads.
ViiV Healthcare’s upcoming presentations at AIDS 2026 will further explore the efficacy of long-acting injectables. The company plans to share data from the LATA and OPERA studies, which evaluate the use of cabotegravir and rilpivirine (CAB+RPV LA) in adolescents and adults with HIV. These studies, led by institutions such as University College London and the London School of Hygiene and Tropical Medicine, aim to provide robust evidence for the adoption of long-acting therapies in clinical practice.
Phase IIIb Trials and Future Research Directions
ViiV Healthcare’s phase IIIb trial, VOGUE, will compare the 2-drug regimen dolutegravir/lamivudine (DTG/3TC) with the 3-drug regimen BIC/FTC/TAF in treatment-naïve adults. The study, which includes participants with high viral loads, seeks to determine the optimal treatment strategy for newly diagnosed patients. Preliminary results suggest that both regimens are effective, but the 3-drug combination may offer advantages in terms of virologic suppression and resistance profiles.
In addition to these trials, ViiV Healthcare will present data on CAB+RPV LA as a pre-exposure prophylaxis (PrEP) option. The CLARITY study, which evaluates the acceptability and efficacy of CAB LA versus lenacapavir injections, will provide insights into patient preferences and adherence patterns. These findings could influence future guidelines for PrEP, particularly in regions with high HIV incidence.
Implications for HIV Treatment and Patient Care
The convergence of real-world data and upcoming clinical trials underscores a shift toward personalized, patient-centered HIV care. By offering alternatives to daily oral therapy, BIC/FTC/TAF and long-acting ART address key barriers to adherence, potentially improving long-term outcomes. However, challenges remain, including the need for infrastructure to support injectable therapies and the cost of new formulations.
Healthcare providers are encouraged to stay informed about the latest research and guidelines as these therapies become more widely available. The data presented at AIDS 2026 will be critical in shaping the next generation of HIV treatment strategies, with a focus on scalability, accessibility, and patient satisfaction. As the field continues to evolve, ongoing monitoring and real-world evaluation will be essential to ensure these innovations meet the needs of diverse populations.
Keep reading
